John G Ullman & Associates Inc. Has $2.01 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

John G Ullman & Associates Inc. lessened its position in United Therapeutics Co. (NASDAQ:UTHR) by 1.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,130 shares of the biotechnology company’s stock after selling 100 shares during the quarter. John G Ullman & Associates Inc.’s holdings in United Therapeutics were worth $2,008,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Neo Ivy Capital Management acquired a new position in shares of United Therapeutics during the 2nd quarter worth approximately $48,000. Atlas Capital Advisors LLC acquired a new position in shares of United Therapeutics during the 4th quarter worth approximately $51,000. Northwestern Mutual Wealth Management Co. increased its position in shares of United Therapeutics by 49.6% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 65 shares during the last quarter. Zions Bancorporation N.A. acquired a new position in shares of United Therapeutics during the 1st quarter worth approximately $66,000. Finally, Quantbot Technologies LP bought a new position in shares of United Therapeutics during the 2nd quarter worth approximately $87,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $232.05, for a total transaction of $835,380.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,166.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $232.05, for a total value of $835,380.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,166.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 13,800 shares of the company’s stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $237.27, for a total value of $3,274,326.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $30,845.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 126,190 shares of company stock valued at $29,672,157. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Stock Performance

UTHR traded up $1.00 during trading on Friday, hitting $237.93. The stock had a trading volume of 395,447 shares, compared to its average volume of 429,529. The company has a 50 day moving average price of $231.20 and a 200-day moving average price of $228.44. The firm has a market cap of $11.20 billion, a price-to-earnings ratio of 11.96 and a beta of 0.52. United Therapeutics Co. has a one year low of $204.44 and a one year high of $261.54. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. The firm had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company’s revenue was up 25.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.67 EPS. As a group, research analysts predict that United Therapeutics Co. will post 23.46 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on UTHR. SVB Leerink began coverage on United Therapeutics in a research note on Monday, February 5th. They set an “outperform” rating and a $330.00 target price for the company. Wedbush reiterated an “outperform” rating and set a $308.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. HC Wainwright reiterated a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. Finally, Wells Fargo & Company lifted their target price on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research note on Thursday, March 7th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $292.67.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.